Etablissement Français du Sang Nouvelle Aquitaine, Place Amélie Raba Léon, CS22010, CEDEX, 33075 Bordeaux, France.
Inserm Bordeaux UMR 1035, 33000 Bordeaux, France.
Biomolecules. 2022 Mar 11;12(3):431. doi: 10.3390/biom12030431.
Steady state peripheral blood (SSPB) contains hematopoietic stem and progenitor cells (HSPCs) presenting characteristics of real hematopoietic stem cells, and thus represents an interesting alternative cell supply for hematopoietic cell transplantation. Development of ex vivo expansion strategies could overcome the low HSPC numbers usually rescued from SSPB. We investigated the effect of alpha lipoic acid (ALA) on ex vivo culture of SSPB CD34 positive (CD34) cells on primitive cell expansion, cell cycle, and oxidative metabolism as estimated by determining the ROS and GSH content. ALA increased the ex vivo expansion of total CD34 cells and of phenotypically defined CD34 HSPCs subpopulations that retained in vivo repopulating capacity, concomitantly to a decreased expansion of differentiating cells. ALA did not modify cell cycle progression nor the proliferation of ex vivo expanded CD34 cells, and coherently did not affect the ROS level. On the contrary, ALA decreased the proliferation and disturbed cell cycle progression of cells reaching a differentiated status, a phenomenon that seems to be associated with a drop in ROS level. Nonetheless, ALA affected the redox status of hematopoietic primitive cells, as it reproducibly increased GSH content. In conclusion, ALA represents an interesting molecule for the improvement of ex vivo expansion strategies and further clinical application in hematopoietic cell transplantation (HCT).
稳定状态外周血 (SSPB) 中含有造血干细胞和祖细胞 (HSPCs),这些细胞具有真正造血干细胞的特征,因此代表了一种有趣的替代造血细胞移植的细胞供应来源。开发体外扩增策略可以克服从 SSPB 中通常挽救的低 HSPC 数量。我们研究了α-硫辛酸 (ALA) 对 SSBP CD34 阳性 (CD34) 细胞体外培养对原始细胞扩增、细胞周期和氧化代谢的影响,方法是通过测定 ROS 和 GSH 含量来评估。ALA 增加了总 CD34 细胞和表型定义的 CD34 HSPC 亚群的体外扩增,同时减少了分化细胞的扩增。ALA 不改变细胞周期进程或体外扩增的 CD34 细胞的增殖,并且不影响 ROS 水平。相反,ALA 减少了达到分化状态的细胞的增殖并扰乱了细胞周期进程,这种现象似乎与 ROS 水平下降有关。尽管如此,ALA 影响了造血原始细胞的氧化还原状态,因为它可重复地增加 GSH 含量。总之,ALA 是改善体外扩增策略和进一步在造血细胞移植 (HCT) 中临床应用的有前途的分子。